Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 9 of 35 / 832 articles
Weight gain is the most commonly cited barrier to quitting—especially among women. Managing weight during cessation is possible with specific strategies: exercise, nutrition, and pharmacological support. The cessation system rarely provides them.
The average smoker cannot accurately compare the risks of smoking and vaping. This is not a failure of the smoker. It's a failure of the information environment—deliberately shaped by public health institutions that prioritized message simplicity over accuracy.
A quality vaping starter kit costs $30-50. A pack of cigarettes costs $10. The smoker who lives paycheck to paycheck can afford the cigarettes. They can't afford the vape. The upfront-cost barrier is a structural obstacle to switching.
Nicotine companies are partnering with pharmaceutical firms to develop and market reduced-risk products. The partnerships combine pharma's regulatory expertise with nicotine's consumer reach. The convergence raises questions about credibility and conflict of interest.
Smoking alters the gut microbiome—the ecosystem of bacteria that regulates digestion, immunity, and even mood. After quitting, the microbiome recovers—slowly. The gut-microbiome dimension of cessation is one of the newest frontiers in nicotine science.
Construction workers smoke at rates far higher than the general population. The job is physically demanding, stressful, and historically tolerant of smoking. The construction industry's smoking rate is an occupational health problem hiding in plain sight.
Most youth nicotine prevention programs are never evaluated. The ones that are evaluated often show no effect—or negative effects. The evaluation gap is a scandal hiding in plain sight: billions spent on programs, almost nothing spent on knowing if they work.
Tobacco farmers in many countries are trapped in debt to the companies that buy their crop. The debt cycle—advances for inputs, repayment at harvest at prices set by the buyer—is a mechanism of control. Breaking it is essential to farmer transition.
The FDA's tobacco regulatory framework is rigid—every product must go through the same PMTA process, regardless of risk. Regulatory flexibility—distinguishing between products based on risk—would save lives. Congress would need to change the law.
The decision to switch from smoking to vaping is not just pharmacological. It's psychological: identity, satisfaction, social norms, and the perceived risk of the alternative. Understanding the psychology of switching is key to making it happen more often.
The technology of quitting has evolved from willpower alone to pharmacotherapy to digital interventions. Each generation of technology has improved quit rates. The next generation—AI, wearables, predictive analytics—could transform cessation.
The tobacco control workforce is demographically homogeneous, ideologically cohesive, and professionally invested in the abstinence framework. Understanding who they are is essential to understanding why nicotine policy looks the way it does.
Flavor bans don't eliminate the demand for flavored vaping products. They eliminate the legal supply. The demand migrates to DIY mixing, cross-border purchasing, and illicit sources. The flavor black market is a predictable—and predicted—consequence.
A growing movement of shareholder activists is pushing nicotine companies to accelerate their transition away from cigarettes. The activists are using the tools of corporate governance—proxy votes, resolutions, engagement. The impact is modest but growing.
The epidemiological evidence is consistent: smokers have lower rates of Parkinson's disease. The mechanism appears to be nicotine's neuroprotective effect. Research on nicotine for cognitive decline is ongoing. The implications are ethically complex.
Correctional officers smoke at elevated rates. The job is stressful, the environment is (now) smoke-free, and the culture of corrections has historically been tolerant of smoking. The correctional officer's smoking is a window into occupational health in the carceral system.
College students are sophisticated consumers of information—and they're skeptical of simplistic prevention messages. Reaching them requires honesty about nicotine's effects (the cognitive benefits, not just the risks) and respect for their capacity to make decisions.
The search for alternative crops to replace tobacco has been ongoing for decades. Some alternatives work—in specific regions, under specific conditions. Most don't pay as well as tobacco. The economic gap is the central challenge of the transition.
The precautionary principle demands near-certainty before endorsing reduced-risk products. The same standard is never demanded of the status quo. The asymmetry in standards of evidence is the central philosophical tension in nicotine policy.
Adolescents are developmentally wired to prioritize peer influence over adult authority. The most effective youth nicotine interventions work with this developmental reality, not against it. Peer-led cessation is more effective than adult-delivered programs.
NRT and prescription cessation medications are effective—when taken as prescribed. Adherence rates are low. Smokers stop using their patches early, skip doses of varenicline, and abandon their quit plans. Understanding why is key to improving outcomes.
The 2009 Tobacco Control Act gave cigarette companies partial immunity from liability for past conduct. The immunity is controversial—and it may be extended to reduced-risk products. The liability question shapes the industry's willingness to innovate.
Vaping in the UK is a public health tool. In the US, it's a regulatory battleground. In Japan, it barely exists—heated tobacco dominates. Vape culture is not universal. It's shaped by policy, history, and consumer preferences.
The major nicotine companies are on an acquisition spree—buying vaping startups, pouch manufacturers, and technology platforms. The strategy is to control the reduced-risk market before it matures. The consolidation has implications for innovation and access.
Products
Select a product to view details, highlights, and technical specifications.
